Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast used its inaugural R&D Day in New York to spotlight its position in allogeneic cell therapy and outline plans to expand its product suite and global reach. The company’s pipeline is anchored by Ryoncil for pediatric SR-aGvHD, with ongoing development in adult SR-aGvHD, biologic-resistant inflammatory bowel disease, heart failure and chronic low back pain, supported by a broad intellectual property estate and scalable manufacturing.
Management detailed a commercial strategy aimed at doubling net revenues as Ryoncil nears a US$100 million milestone since last year’s launch, underscoring growing market traction. The company highlighted progress toward label extensions for Ryoncil in adult and pediatric rare diseases, reported imminent completion of Phase 3 enrollment for chronic low back pain, and announced the acquisition of a Mayo Clinic–developed CAR technology platform to enhance its mesenchymal cell products, moves that collectively strengthen its long-term growth and competitive positioning in regenerative medicine.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company specializing in allogeneic, off-the-shelf cellular medicines targeting severe and life-threatening inflammatory conditions. Its lead product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and the company is advancing additional indications and products for inflammatory and degenerative diseases globally.
Average Trading Volume: 4,173,671
Technical Sentiment Signal: Hold
Current Market Cap: A$2.75B
See more data about MSB stock on TipRanks’ Stock Analysis page.